A day of anticipation ended in disappointment as Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals Inc. received a complete response letter late Friday from the FDA for injectable Relistor (methylnaltrexone bromide) for opioid-induced constipation in adult patients with chronic, noncancer pain, which has not responded to treatment with laxatives.